Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
Clinical trial NCT01828021 · COMPLETED
Trial details
- NCT number
- NCT01828021
- Sponsor
- MacroGenics
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-03-01
- Primary completion
- 2016-12-07
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.